Back to Results

Adaptimmune Therapeutics Plc (ADAPY)

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company focused on cell therapies for cancer, with activities in the United States and the United Kingdom. The company’s listed security is an ADR, classified as a depositary receipt representing common stock, and it trades on OTC Markets under the symbol ADAP.Y. Adaptimmune’s pipeline includes TECELRA (afami-cel) for adults with unresectable or metastatic synovial sarcoma, Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, which is in Phase 1 testing for head and neck cancer. It is also developing T-cell therapies targeting PRAME and CD70. The company has collaboration arrangements with Galápagos, Noile-Immune Biotech, and MD Anderson Cancer Center. Founded in 2008, Adaptimmune is headquartered in Abingdon, United Kingdom.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-ADAP.Y
$0.039
50.4% Upside
Bargain
$1.50 5,669.2% Upside
Not available
Bargain
Weak
0.0%
November 12, 2026
0.2x
1.2x
6.971 M
-4.713 M
66.3%
99.4%
-47.2
156.8%
Valuation • Fair Value

Adaptimmune Therapeutics Plc (OTC-ADAP.Y) Fair Value by Valuation Model

Review the available estimates for Adaptimmune Therapeutics Plc (OTC-ADAP.Y), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.039

Estimated upside of 50.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.039

Comparable-company valuation reference.

Analyst Price Target

$1.50 5,669.2% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Adaptimmune Therapeutics Plc (OTC-ADAP.Y)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

5.924 M

Current operating scale indicator.

Revenue Forecast

71.973 M

Forward revenue estimate.

EBITDA

-57.491 M

Current operating profitability reference.

EBITDA Forecast

-55.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Adaptimmune Therapeutics Plc (OTC-ADAP.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Adaptimmune Therapeutics Plc (OTC-ADAP.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

5

Mid-range quality score.

Altman Z-Score

-47.2

Lower score that deserves closer risk review.

FCF / Net Income

156.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Adaptimmune Therapeutics Plc (OTC-ADAP.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Adaptimmune Therapeutics Plc (OTC-ADAP.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Adaptimmune Therapeutics Plc (OTC-ADAP.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Adaptimmune Therapeutics Plc (OTC-ADAP.Y) Stock FAQ

Data-supported answers about Adaptimmune Therapeutics Plc (OTC-ADAP.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.039
Estimated upside 50.4%
Valuation Rating
Undervalued
Estimated upside of 50.4%
Analyst Target
$1.50 5,669.2% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is $0.039. This implies an estimated upside of 50.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 50.4% versus the current market price.

The available analyst price target for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is $1.50 5,669.2% Upside.

The current financial health read for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is November 12, 2026.

The latest available data indicates no current dividend yield for Adaptimmune Therapeutics Plc (OTC-ADAP.Y).

The current market capitalization listed for Adaptimmune Therapeutics Plc is 6.971 M.

The current enterprise value listed for Adaptimmune Therapeutics Plc is -4.713 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Adaptimmune Therapeutics Plc is OTC-ADAP.Y, and the stock is listed on OTC Markets.

Adaptimmune Therapeutics Plc (OTC-ADAP.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Adaptimmune Therapeutics Plc is 66.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Adaptimmune Therapeutics Plc is 99.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B